Cargando…

Psychobiotics in mental health, neurodegenerative and neurodevelopmental disorders

Psychobiotics are a group of probiotics that affect the central nervous system (CNS) related functions and behaviors mediated by the gut-brain-axis (GBA) via immune, humoral, neural, and metabolic pathways to improve not only the gastrointestinal (GI) function but also the antidepressant and anxioly...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheng, Li-Hao, Liu, Yen-Wenn, Wu, Chien-Chen, Wang, Sabrina, Tsai, Ying-Chieh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taiwan Food and Drug Administration 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9307042/
https://www.ncbi.nlm.nih.gov/pubmed/31324280
http://dx.doi.org/10.1016/j.jfda.2019.01.002
_version_ 1784752680993816576
author Cheng, Li-Hao
Liu, Yen-Wenn
Wu, Chien-Chen
Wang, Sabrina
Tsai, Ying-Chieh
author_facet Cheng, Li-Hao
Liu, Yen-Wenn
Wu, Chien-Chen
Wang, Sabrina
Tsai, Ying-Chieh
author_sort Cheng, Li-Hao
collection PubMed
description Psychobiotics are a group of probiotics that affect the central nervous system (CNS) related functions and behaviors mediated by the gut-brain-axis (GBA) via immune, humoral, neural, and metabolic pathways to improve not only the gastrointestinal (GI) function but also the antidepressant and anxiolytic capacity. As a novel class of probiotics, the application of psychobiotics has led researchers to focus on a new area in neuroscience. In the past five years, some psychobiotics strains were reported to inhibit inflammation and decreased cortisol levels, resulting in an amelioration of the symptoms of anxiety and depression. Psychobiotics are efficacious in improving neurodegenerative and neurodevelopmental disorders, including autism spectrum disorder (ASD), Parkinson’s disease (PD) and Alzheimer’s disease (AD). Use of psychobiotics can improve GI function, ASD symptoms, motor functions of patients with PD and cognition in patients with AD. However, the evidence for the effects of psychobiotics on mental and neurological conditions/ disorders remains limited. Further studies of psychobiotics are needed in order to determine into their effectiveness and mechanism as treatments for various psychiatric disorders in the future.
format Online
Article
Text
id pubmed-9307042
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Taiwan Food and Drug Administration
record_format MEDLINE/PubMed
spelling pubmed-93070422022-08-09 Psychobiotics in mental health, neurodegenerative and neurodevelopmental disorders Cheng, Li-Hao Liu, Yen-Wenn Wu, Chien-Chen Wang, Sabrina Tsai, Ying-Chieh J Food Drug Anal Review Article Psychobiotics are a group of probiotics that affect the central nervous system (CNS) related functions and behaviors mediated by the gut-brain-axis (GBA) via immune, humoral, neural, and metabolic pathways to improve not only the gastrointestinal (GI) function but also the antidepressant and anxiolytic capacity. As a novel class of probiotics, the application of psychobiotics has led researchers to focus on a new area in neuroscience. In the past five years, some psychobiotics strains were reported to inhibit inflammation and decreased cortisol levels, resulting in an amelioration of the symptoms of anxiety and depression. Psychobiotics are efficacious in improving neurodegenerative and neurodevelopmental disorders, including autism spectrum disorder (ASD), Parkinson’s disease (PD) and Alzheimer’s disease (AD). Use of psychobiotics can improve GI function, ASD symptoms, motor functions of patients with PD and cognition in patients with AD. However, the evidence for the effects of psychobiotics on mental and neurological conditions/ disorders remains limited. Further studies of psychobiotics are needed in order to determine into their effectiveness and mechanism as treatments for various psychiatric disorders in the future. Taiwan Food and Drug Administration 2019-02-10 /pmc/articles/PMC9307042/ /pubmed/31324280 http://dx.doi.org/10.1016/j.jfda.2019.01.002 Text en © 2019 Taiwan Food and Drug Administration https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC-BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) ).
spellingShingle Review Article
Cheng, Li-Hao
Liu, Yen-Wenn
Wu, Chien-Chen
Wang, Sabrina
Tsai, Ying-Chieh
Psychobiotics in mental health, neurodegenerative and neurodevelopmental disorders
title Psychobiotics in mental health, neurodegenerative and neurodevelopmental disorders
title_full Psychobiotics in mental health, neurodegenerative and neurodevelopmental disorders
title_fullStr Psychobiotics in mental health, neurodegenerative and neurodevelopmental disorders
title_full_unstemmed Psychobiotics in mental health, neurodegenerative and neurodevelopmental disorders
title_short Psychobiotics in mental health, neurodegenerative and neurodevelopmental disorders
title_sort psychobiotics in mental health, neurodegenerative and neurodevelopmental disorders
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9307042/
https://www.ncbi.nlm.nih.gov/pubmed/31324280
http://dx.doi.org/10.1016/j.jfda.2019.01.002
work_keys_str_mv AT chenglihao psychobioticsinmentalhealthneurodegenerativeandneurodevelopmentaldisorders
AT liuyenwenn psychobioticsinmentalhealthneurodegenerativeandneurodevelopmentaldisorders
AT wuchienchen psychobioticsinmentalhealthneurodegenerativeandneurodevelopmentaldisorders
AT wangsabrina psychobioticsinmentalhealthneurodegenerativeandneurodevelopmentaldisorders
AT tsaiyingchieh psychobioticsinmentalhealthneurodegenerativeandneurodevelopmentaldisorders